COVID-19, Oxidative Stress, and Neuroinflammation in the Depression Route.
Level 5 - mechanism / opinion, no new human data
Narrative review describing biological mechanisms without systematic search methods or original clinical data.
PubMed 35322375 · doi:10.1007/s12031-022-02004-y
What was done
The authors conducted a narrative review synthesizing literature on the mechanistic pathways linking COVID-19 infection, oxidative stress, peripheral hyperinflammation, and neuroinflammation to the onset or exacerbation of major depressive disorder (MDD).
What was found
The abstract provides no empirical numbers, effect sizes, or study counts. It describes mechanistic pathways wherein COVID-19 hyperinflammation triggers the hypothalamic-pituitary-adrenal (HPA) axis and indoleamine-2,3-dioxygenase (IDO) enzyme activation, reducing tryptophan and elevating neurotoxic kynurenine pathway metabolites that promote glial activation, neuroinflammation, and neuronal death in MDD.
Why it matters
This review outlines biological pathways connecting systemic viral inflammation to depressive disorders, identifying the IDO-kynurenine axis as a potential target for therapeutic investigation in post-COVID-19 neuropsychiatric conditions.
Limits
As a narrative review, it lacks a systematic search protocol, formal quality appraisal, and primary empirical data. No sample size, effect size, or human clinical trial outcomes are reported in the abstract.
Cited by
- supports COVID-19 infection is associated with viral brain entry, blood-brain barrier disruption, increased inflammatory cytokines (including IL-1 beta, IL-6, IL-10, and TNF-alpha), NMDA receptor stimulation, and kynurenine pathway activation producing quinolinic acid.